Related references
Note: Only part of the references are listed.Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy
Shu-Yu Lin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1
Yi-Hui Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1
William P. Malachowski et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway
Amy B. Dounay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1
Georgios Pantouris et al.
AMINO ACIDS (2014)
Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase
Georgios Pantouris et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information
Marco Biasini et al.
NUCLEIC ACIDS RESEARCH (2014)
Crystal Structures and Structure Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors
Shingo Tojo et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012)
Eduard Dolusic et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
Crystal structure of Drosophila melanogaster tryptophan 2,3-dioxygenase reveals insights into substrate recognition and catalytic mechanism
Wei Huang et al.
JOURNAL OF STRUCTURAL BIOLOGY (2013)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
Eduard Dolusic et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
K. L. Vine et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Reassessment of the Reaction Mechanism in the Heme Dioxygenases
Nishma Chauhan et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Emerging drugs for the treatment of metastatic renal cancer
Wolfram E. Samlowski et al.
EXPERT OPINION ON EMERGING DRUGS (2007)
Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase
Farhad Forouhar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Crystal structure of human indoleamine 2,3-dioxygenase:: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase
H Sugimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Endogenous kynurenines as targets for drug discovery and development
TW Stone et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Oxidation of indole by cytochrome P450 enzymes
EMJ Gillam et al.
BIOCHEMISTRY (2000)
Share Paper
